Abstract:Introduction: Prostate cancer (PC) ranks as the second most frequent type of cancer in men and is the fourth largest cause of mortality worldwide. Androgenic hormones such as testosterone and dihydrotestosterone are crucial for the development and progression of the prostate gland. Androgenic hormones bind to androgen receptors (AR) and trigger the synthesis of many genes that stimulate the growth of prostate cells, initiating PC growth. Apalutamide (APL) is a non-steroidal antiandrogen drug used to treat PC; however, it also causes a variety of toxicities and resistance during the treatment. Methods: The purpose of this study was to computationally identify new and safer analogues of APL, focusing on improved pharmacokinetic properties and reduced toxicity. Drug likeness (DL) and drug score (DS) were also calculated. Docking studies on the designed analogues were conducted to predict their binding affinities and compare their orientations with the ligands in the original crystal structure. Molecular dynamics (MD) simulation of docked ligands was done using Schrödinger suite. Results: We generated a total of 1,415 analogues for different groups of APL using the bioisosteric approach. We selected 80 bioisosteres based on pharmacokinetic profiles, DL and DS score predictions, and found that the designed APL bioisosteres were optimal to good compared to APL. Analogues APL19, APL35, APL43, APL76, and APL80, formed hydrogen bonds with protein (PDB ID: 5T8E) which is similar hydrogen bonding to the standard (APL). The MD simulation result confirmed that APL43 and APL80 complexes were stable during the 100 nS run. Discussion: The results suggest that the APL analogues, particularly APL43 and APL80, are predicted to be potential antiandrogen drugs for the treatment of prostate cancer.

Synthesis and Modeling of Novel Α-Aminoalkylphosphonate Ester Derivatives As Potent Inhibitors of Prostate-Specific Antigen; A Comparison Study

Structure-Based Drug Design of Diphenyl Α-Aminoalkylphosphonates As Prostate-Specific Antigen Antagonists.

Structure-Based Design Of Tripeptide Derivatives Of α-Aminoalkylphosphonate Esters For Prostate-Specific Antigen Inhibition

Structural optimization, biological evaluation, and application of peptidomimetic prostate specific antigen inhibitors

Synthesis, Biological Evaluation and Molecular Docking of 4-Amino-2h-benzo[h]chromen-2-one (ABO) Analogs Containing the Piperazine Moiety.

Novel Β- and Γ-Amino Acid-Derived Inhibitors of Prostate-Specific Membrane Antigen

Design, Synthesis and Biological Evaluation of 1-Methyl-1h-pyrazole-5-carboxamide Derivatives As Novel Anti-Prostate Cancer Agents.

Exploring novel Apalutamide analogues as potential therapeutics for prostate cancer: design, molecular docking investigations and molecular dynamics simulation

Design, Synthesis and Biological Evaluation of Novel 3-Oxo-4-oxa-5α-androst-17β-amide Derivatives As Dual 5Α-Reductase Inhibitors and Androgen Receptor Antagonists.

Discovery of novel 5-methyl-1H-pyrazole derivatives as potential anti-prostate cancer agents: design, synthesis, molecular modeling and biological evaluation.

Synthesis and Optimization of Small Molecule Inhibitors of Prostate Specific Antigen

Exploration on natural product anibamine side chain modification toward development of novel CCR5 antagonists and potential anti-prostate cancer agents

Design, synthesis and biological evaluation of novel thiohydantoin derivatives as potent androgen receptor antagonists for the treatment of prostate cancer

Design and Characterization of Squaramic Acid-Based Prostate-Specific Membrane Antigen Inhibitors for Prostate Cancer.

Design, Synthesis and Biological Evaluation of Thiohydantoin Derivatives As Novel Anti-prostate Cancer Agents.

Identification of Novel Androgen Receptor Degrading Agents to Treat Advanced Prostate Cancer

Discovery of 5-Nitro-n-(3-(trifluoromethyl)phenyl) Pyridin-2-amine As a Novel Pure Androgen Receptor Antagonist Against Antiandrogen Resistance

Discovery and Identification of Pyrazolopyramidine Analogs as Novel Potent Androgen Receptor Antagonists

Design, Synthesis, and Biological Evaluation of Novel Androst-17Β-amide Structurally Related Compounds As Dual 5Α-Reductase Inhibitors and Androgen Receptor Antagonists.

1-Benzyloxy-5-phenyltetrazole derivatives highly active against androgen receptor-dependent prostate cancer cells

The design, synthesis and anti-tumor mechanism study of new androgen receptor degrader